Cargando…

856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort

BACKGROUND: Several novel biomarkers have been studied in predicting clinical outcomes in patients with COVID-19. Our study aimed to study C-terminal proendothelin-1 (CT-proET-1) and Soluble fms-like tyrosine kinase-1 (sFlt-1) as predictors of clinical outcomes in a COVID-19 patient cohort from a US...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Johnny, Atallah, Natalie, Panossian, Vahe, Warren, Hailey, Inlall, Damian, Schwabe, Andrej, Johannes, Sascha, Wiemer, Jan, Mansour, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676935/
http://dx.doi.org/10.1093/ofid/ofad500.901
_version_ 1785150011256864768
author Atallah, Johnny
Atallah, Natalie
Panossian, Vahe
Warren, Hailey
Inlall, Damian
Schwabe, Andrej
Johannes, Sascha
Wiemer, Jan
Mansour, Michael
author_facet Atallah, Johnny
Atallah, Natalie
Panossian, Vahe
Warren, Hailey
Inlall, Damian
Schwabe, Andrej
Johannes, Sascha
Wiemer, Jan
Mansour, Michael
author_sort Atallah, Johnny
collection PubMed
description BACKGROUND: Several novel biomarkers have been studied in predicting clinical outcomes in patients with COVID-19. Our study aimed to study C-terminal proendothelin-1 (CT-proET-1) and Soluble fms-like tyrosine kinase-1 (sFlt-1) as predictors of clinical outcomes in a COVID-19 patient cohort from a US-based multicenter trial. METHODS: Data from the Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial was used in this study. Patients with biomarker determinations, and not admitted to the intensive care unit (ICU) on admission, were included. Median concentrations of CT-proET-1 (83.6 pmol/L) and sFlt-1 (81.3 pg/mL) were used as cutoffs in predicting clinical outcomes. RESULTS: Out of 169 patients, 10.7% mechanically ventilated or dead within 28 days of admission. CT-proET1 concentrations in patients who were mechanically ventilated or dead within 28 days were significantly higher than those who were not (median 119.6 vs 79.1 pmol/L, p=0.001), and higher in patients who were admitted to the ICU during hospitalization compared to those who were not (median 114.5 vs 80.6 pmol/L, p=0.005). Significantly higher sFlt-1 concentrations were seen in patients who were admitted to the ICU compared to those who were not (median 96.0 vs 80.7 pg/mL, p=0.041). The sensitivity, specificity, PPV and NPV of CT-proET-1 with cutoff 83.6 pmol/L in predicting mechanical ventilation or death were 83%, 54%, 18%, and 96%, respectively, with an AUC of 0.75. As for the sFlt-1 cutoff of 81.3 pg/mL in predicting mechanical ventilation or death, the sensitivity, specificity, PPV and NPV were 61%, 54%, 14%, and 92%, with an AUC of 0.59. CONCLUSION: CT-proET-1 and sFlt-1 function as valuable novel biomarkers in predicting clinical outcomes in COVID-19, with lower levels predicting better outcomes. Further studies are needed to better understand their role in other upper respiratory viral illnesses. DISCLOSURES: Michael Mansour, MD, PhD, Thermofisher: Grant/Research Support
format Online
Article
Text
id pubmed-10676935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106769352023-11-27 856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort Atallah, Johnny Atallah, Natalie Panossian, Vahe Warren, Hailey Inlall, Damian Schwabe, Andrej Johannes, Sascha Wiemer, Jan Mansour, Michael Open Forum Infect Dis Abstract BACKGROUND: Several novel biomarkers have been studied in predicting clinical outcomes in patients with COVID-19. Our study aimed to study C-terminal proendothelin-1 (CT-proET-1) and Soluble fms-like tyrosine kinase-1 (sFlt-1) as predictors of clinical outcomes in a COVID-19 patient cohort from a US-based multicenter trial. METHODS: Data from the Boston Area COVID-19 Consortium (BACC) Bay Tocilizumab Trial was used in this study. Patients with biomarker determinations, and not admitted to the intensive care unit (ICU) on admission, were included. Median concentrations of CT-proET-1 (83.6 pmol/L) and sFlt-1 (81.3 pg/mL) were used as cutoffs in predicting clinical outcomes. RESULTS: Out of 169 patients, 10.7% mechanically ventilated or dead within 28 days of admission. CT-proET1 concentrations in patients who were mechanically ventilated or dead within 28 days were significantly higher than those who were not (median 119.6 vs 79.1 pmol/L, p=0.001), and higher in patients who were admitted to the ICU during hospitalization compared to those who were not (median 114.5 vs 80.6 pmol/L, p=0.005). Significantly higher sFlt-1 concentrations were seen in patients who were admitted to the ICU compared to those who were not (median 96.0 vs 80.7 pg/mL, p=0.041). The sensitivity, specificity, PPV and NPV of CT-proET-1 with cutoff 83.6 pmol/L in predicting mechanical ventilation or death were 83%, 54%, 18%, and 96%, respectively, with an AUC of 0.75. As for the sFlt-1 cutoff of 81.3 pg/mL in predicting mechanical ventilation or death, the sensitivity, specificity, PPV and NPV were 61%, 54%, 14%, and 92%, with an AUC of 0.59. CONCLUSION: CT-proET-1 and sFlt-1 function as valuable novel biomarkers in predicting clinical outcomes in COVID-19, with lower levels predicting better outcomes. Further studies are needed to better understand their role in other upper respiratory viral illnesses. DISCLOSURES: Michael Mansour, MD, PhD, Thermofisher: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10676935/ http://dx.doi.org/10.1093/ofid/ofad500.901 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Atallah, Johnny
Atallah, Natalie
Panossian, Vahe
Warren, Hailey
Inlall, Damian
Schwabe, Andrej
Johannes, Sascha
Wiemer, Jan
Mansour, Michael
856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
title 856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
title_full 856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
title_fullStr 856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
title_full_unstemmed 856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
title_short 856. CT-proET-1 and sFlt-1 as Predictors of Clinical Outcomes in a COVID-19 US Cohort
title_sort 856. ct-proet-1 and sflt-1 as predictors of clinical outcomes in a covid-19 us cohort
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676935/
http://dx.doi.org/10.1093/ofid/ofad500.901
work_keys_str_mv AT atallahjohnny 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT atallahnatalie 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT panossianvahe 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT warrenhailey 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT inlalldamian 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT schwabeandrej 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT johannessascha 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT wiemerjan 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort
AT mansourmichael 856ctproet1andsflt1aspredictorsofclinicaloutcomesinacovid19uscohort